Prognostic and predictive factors for gliomas in adults;Facteurs pronostiques et prédictifs de réponse des gliomes cérébraux de l'adulte

Bulletin du Cancer

Volumn 96, Issue 4, 2009, Pages 357-367

  Frenel, J S ^a   Botti, M ^a   Loussouarn, D ^b   Campone, M ^a  

^a Institut de Cancérologie de Nantes Atlantique   (France)

^b CHU de Nantes   (France)

Author keywords

1p 19q deletion; Glioma; MGMT methylation; Predictive factor; Prognostic factor

Indexed keywords

6 O BENZYLGUANINE; ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IRINOTECAN; LOMUSTINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; RAPAMYCIN; TEMOZOLOMIDE; VINCRISTINE;

ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; CLINICAL TRIAL; DISEASE SEVERITY; GLIOBLASTOMA; GLIOMA; GROUPS BY AGE; HISTOLOGY; HUMAN; MOLECULAR BIOLOGY; NEUROLOGIC DISEASE; OLIGODENDROGLIOMA; PHYSICAL PERFORMANCE; PROGNOSIS; REVIEW; SCORING SYSTEM; TUMOR VOLUME;

ADULT; AGE FACTORS; BRAIN NEOPLASMS; CHROMOSOME DELETION; GLIOMA; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 66349117115     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0776     Document Type: Review

References (52)

1. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G, Burger PC, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002 ; 61 (3) : 215-225 (discussion 226-9).
2. Lang FF, Gilbert MR. Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol 2006 ; 24 (8) : 1236-1245 (Pubitemid 46622026)
3. Smith JS, Perry A, Borell TJ, Lee HK, O'Fallon J, Hosek SM, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 2000 ; 18 (3) : 636-645 (Pubitemid 30078545)
4. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (Berl) 2004 ; 108 (1) : 49-56. (Pubitemid 38961073)
5. Karim AB, Afra D, Cornu P, Bleehan N, Schraub S, De Witte O, et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 2002 ; 52 (2) : 316-324 (Pubitemid 34170840)
6. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Thomas DG, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996 ; 36 (3) : 549-556 (Pubitemid 26404297)
7. Keles GE, Lamborn KR, Berger MS. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor-influencing outcome. J Neurosurg 2001 ; 95 (5) : 735-745 (Pubitemid 33043344)
8. Berger MS, Deliganis AV, Dobbins J, Keles GE. The effect of extent of resection on recurrence in patients with low-grade cerebral hemisphere gliomas. Cancer 1994 ; 74 (6) : 1784-1791 (Pubitemid 24301834)
9. Schmidt MH, Berger MS, Lamborn KR, Aldape K, McDermott MW, Prados MD, et al. Repeated operations for infiltrative low-grade gliomas without intervening therapy. J Neurosurg 2003 ; 98 (6) : 1165-1169 (Pubitemid 36617915)
10. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 2002 ; 20 (8) : 2076-2084 (Pubitemid 34408798)
11. Hoang-Xuan K, Capelle L, Kujas M, Taillibert S, Duffau H, Lejeune J, et al. Témozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004 ; 22 (15) : 3133-3138 (Pubitemid 41103727)
12. Buckner JC, Gesme Jr. D, O'Fallon JR, Hammack JE, Stafford S, Brown PD, et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 2003 ; 21 (2) : 251-255 (Pubitemid 46606153)
13. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer 2005 ; 103 (4) : 802-809 (Pubitemid 40216410)
14. Curran Jr. WJ, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993 ; 85 (9) : 704-710 (Pubitemid 23133591)
15. Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002 ; 359 (9311) : 1011-1018
16. Lacroix M, Abi-Said D, Fourney DR, Gokaslan ZL, Shi W, DeMonte F, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 2001 ; 95 (2) : 190-198 (Pubitemid 32799739)
17. Winger MJ, Macdonald DR, Cairncross JG. Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. J Neurosurg 1989 ; 71 (4) : 487-493 (Pubitemid 19244261)
18. Oh J, Henry RG, Pirzkall A, Lu Y, Li X, Catalaa I, et al. Survival analysis in patients with glioblastoma multiforme: predictive value of choline to N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004 ; 19 (5) : 546-554 (Pubitemid 38619916)
19. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 1994 ; 145 (5) : 1175-1190 (Pubitemid 24345665)
20. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998 ; 90 (19) : 1473-1479 (Pubitemid 28482012)
21. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR, Stemmer-Rachamimov AO, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res 2001 ; 7 (4) : 839-845 (Pubitemid 32708719)
22. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys 2000 ; 48 (3) : 825-830
23. McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, et al. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 2005 ; 104 (7) : 1468-1477 (Pubitemid 41356162)
24. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, Brachman D, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006 ; 24 (18) : 2707-2714 (Pubitemid 46630566)
25. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006 ; 24 (18) : 2715-2722 (Pubitemid 46630567)
26. Hoang-Xuan K, He J, Huguet S, Mokhtari K, Marie Y, Kujas M, et al. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression. Neurology 2001 ; 57 (7) : 1278-1281 (Pubitemid 32947388)
27. Bortolotto S, Chiado-Piat L, Cavalla P, Bosone I, Chio A, Mauro A, et al. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J Cancer 2000 ; 88 (4) : 554-557
28. Sanson M, Leuraud P, Aguirre-Cruz L, He J, Marie Y, Cartalat- Carel S, et al. Analysis of loss of chromosome 10q, DMBT1 homozygous deletions, and PTEN mutations in oligodendrogliomas. J Neurosurg 2002 ; 97 (6) : 1397-1401 (Pubitemid 35424296)
29. Backlund LM, Nilsson BR, Liu L, Ichimura K, Collins VP. Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. Br J Cancer 2005 ; 93 (1) : 124-130 (Pubitemid 41076260)
30. Aldape KD, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 2004 ; 63 (7) : 700-707 (Pubitemid 38891086)
31. Liu L, Backlund LM, Nilsson BR, Grander D, Ichimura K, Goike HM, et al. Clinical significance of EGFR amplification and the aberrant EGFRvIII transcript in conventionally treated astrocytic gliomas. J Mol Med 2005 ; 83 (11) : 917-926 (Pubitemid 41598692)
32. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Nakamura H, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003 ; 63 (20) : 6962-6970 (Pubitemid 37322983)
33. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005 ; 11 (4) : 1462-1466 (Pubitemid 40315227)
34. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007 ; 25 (16) : 2288-2294 (Pubitemid 46954657)
35. Macdonald DR, Gaspar LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990 ; 27 (5) : 573-574 (Pubitemid 20149980)
36. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994 ; 12 (10) : 2013-2021
37. Stupp R, Pica A, Mirimanoff RO, Michielin O. A practical guide for the management of gliomas. Bull Cancer 2007 ; 94 (9) : 817-822 (Pubitemid 47605611)
38. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, et al. Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 2003 ; 21 (13) : 2525-2528 (Pubitemid 46606334)
39. Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, et al. Correlations between O6-methylguanine-DNA-methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol 2006 ; 24 (29) : 4746-4753 (Pubitemid 46630938)
40. Kouwenhoven MC, Kros JM, French PJ, Biemond-ter Stege EM, Graveland WJ, Taphoorn MJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 2006 ; 42 (15) : 2499-2503 (Pubitemid 44468379)
41. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G. Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 2005 ; 113 (3) : 379-385 (Pubitemid 40038704)
42. Paus C, Murat A, Stupp R, Regli L, Hegi M. Role of MGMT and clinical applications in brain tumours. Bull Cancer 2007 ; 94 (9) : 769-773 (Pubitemid 47605605)
43. Silber JR, Mueller BA, Ewers TG, Berger MS. Comparison of O6- methylguanine-DNA-methyltransferase activity in brain tumors and adjacent normal brain. Cancer Res 1993 ; 53 (14) : 3416-3420 (Pubitemid 23223319)
44. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000 ; 343 (19) : 1350-1354
45. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002 ; 20 (5) : 1375-1382 (Pubitemid 34177445)
46. Hegi ME, Diserens AC, Godard S, Dietrich PY, Regli L, Ostermann S, et al. Clinical trial substantiates the predictive value of O- 6-methylguanine-DNA- methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004 ; 10 (6) : 1871-1874 (Pubitemid 38375541)
47. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 ; 352 (10) : 987-996 (Pubitemid 40349501)
48. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005 ; 352 (10) : 997-1003. (Pubitemid 40349502)
49. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005 ; 353 (19) : 2012-2024 (Pubitemid 41609094)
50. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, et al. Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008 ; 5 (1) : e8.
51. Vredenburgh JJ, Desjardins A, Herndon 2nd JE, Marcello J, Reardon DA, Quinn JA, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007 ; 25 (30) : 4722-4729
52. Sathornsumetee S, Cao Y, Marcello JE, Herndon 2nd JE, McLendon RE, Desjardins A, et al. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 2008 ; 26 (2) : 271-278